EPHA4 and amyotrophic lateral sclerosis: Epha4-specific nanobodies [39], an EphA4 receptor soluble antagonist [40] and selective Epha4-binding compounds [41], were developed to treat ALS and delivered encouraging results in delaying disease progression in the SOD1G93A model.